Jackie Hunter is CEO of BenevolentBio. Having worked for global pharmaceutical organisations including GSK, Proimagen and OI Pharma, Jackie has a wealth of knowledge and experience to draw on when it comes to talking about the challenges currently facing the pharmaceutical industry; the application of AI in drug development or the global conferences she has attended and contributed to.
Professor Jackie Hunter, CEO of BenevolentBio, writes for The Huffington Post on diversity in the AI industry and how it has the chance to embrace it or risk going the same way as many other industries.
Jackie Hunter explains why we need to encourage diversity in AI in a co-ordinated effort across the home, at school, at university and into the workplace.
On the surface science policy may appear to be rather a dry subject, but it is fundamental to academic research and its positive knock-on effect for innovation in industry.
Let’s talk pharmaceutical innovation, and in doing so let’s be honest and perhaps a little controversial. Last year the CEO of Regeneron, Leonard Schleifer, stood up at the Forbes Healthcare Summit in New York and said something surprisingly candid and revealing.
It’s the last week before Christmas and a good time for reflection, to pause for breath and to think about what the next year will bring.
10 years ago I attended a symposium looking at the future of pharmacology and healthcare.
These are truly exciting times for artificial intelligence (“AI”) and bioscience. This month, together with The Crick and Turing Institutes and the Wellcome Trust, we co-hosted the first of what we anticipate will be an annual symposium on ‘Artificial Intelligence in Bioscience’.